The Hamad Laboratory

Recent Publications

Most Recent Publications: 2012-Present

  1. Hamad AR. Ahmed R, Donner T, And Fousteri G. B cell-targeted immunotherapy for type 1 diabetes: what can make it work? Discov Med. 2016 Mar;21(115):213-9. PMID: 27115172
  2. Fousteri G, Ippolito E, Ahmed R, Hamad AR. Beta-cell specific autoantibodies: Are they just an indicator of type 1 diabetes? Curr Diabetes Rev. 2016, April 26 [Epub ahead of print]. PMID: 27117244
  3. Noel S, Martina MN, Bandapalle S, Potteti H, Hamad ARA, Rabb, H. Double negative αβT cells are early responders to acute kidney injury in mice and found in human kidney Journal of the American Society of Nephrology, In press
  4. Martina MN, Noel S, Bandapalle S, Potteti H, Rabb, H, Hamad ARA. T lymphocyte-specific activation of Nrf2 protects from AKI. Journal of the American Society of Nephrology. In press
  5. Ankit Saxena, Sam Khosraviani, Sanjeev Noel, Divya Mohan, Thomas Donner, Hamad ARA. Interleukin-10 paradox. A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine, 74:27. 2015: 25481648
  6. Martina MN, Noel S, Saxena A, Rabb H, Hamad AR. Double Negative (DN) αβT Cells: Misperception and overdue recognition. Immunol Cell Biol, 93:305. 2015. PMID: 25420721
  7. Martina M, Bandapalle S, Rabb H, Hamad ARA. Isolation of double negative T cells from the kidney. J Vis Exp. 16;(87). doi: 10.3791/51192. 2014. PMID: 2534821
  8. Maria Martina, Abdel Rahim Hamad and H. Rabb. T lymphocytes and acute kidney injury. Nephron Clin Pract; 127:51-5. 2014. PMID:25343821
  9. Noel S, Martina-Lingua MN, Bandapalle S, Pluznick J, Hamad AR, Peterson DA, Rabb H. Intestinal microbiota-kidney cross talk in acute kidney injury and chronic kidney disease. Nephron Clin Pract.;127:139. 2014. PMID: 25343838.
  10. Lourdes Ramirez and Abdel Rahim Hamad. Understanding autoimmune diabetes: 20 years after the generation of BDC 2.5 islet reactive TCR transgenic mice. Invited editorial. World Journal of Diabetes. World J Diabetes, 2013 4:88-91. PMID: 23961318
  11. Donner, T., S. Uddin, K. Arkara, Abdel Rahim Hamad. Potentials of FasL ligand (apoptosis inducing -molecule) as a unconventional therapeutic target in type 1 diabetes. Front Immunol. 2012; 3:196. PMID: 22807927

Additional recent publications of importance to the field (in chronological order) out of 34 publications

  1. Xiao, X., Mohamood, A.S., Uddin, S., Gutfreund, R., Nakata, S., Marshall, A., Kimura, H., Caturegli, P., Womer, K.L., Huang, Y., J. Schneck, Hideo Yagita and Abdel Rahim Hamad. Inhibition of Fas ligand in NOD mice unmasks a protective role for IL-10 against insulitis development. Am J Pathol. 2011;179:752-32. PMID 21718680.
  2. Immunotherapy for Type 1 Diabetes: Necessity, Challenges and Unconventional Opportunities. Type 1 Diabetes / Book 1", ISBN 978-953-307. 2011.
  3. Mohamood AS, Trujillo CJ, Zheng D, Jie C, Murillo FM, Schneck JP and A. R. Hamad. Gld mutation of Fas ligand increases the frequency and upregulates cell survival genes in CD25+CD4+ Treg Cells. Int Immunol. 2006; 18:1265. PMID 16769751
  4. Mohamood A., M Guler, X. Zuoxiang, D. Zheng, Y. Wang, H. Yagita, J Schneck and A. R. Hamad. 2007. Protection from autoimmune diabetes and T cell lymphoproliferation-induced by FasL mutation are differentially regulated and can be uncoupled pharmacologically. Am J Pathol 171:97. PMID 17591957